All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of polycythemia vera (PV)?
Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?
Kiladjian discusses factors that are independently associated with a positive outcome with ropeginterferon alfa-2b therapy. In a cohort of patients from Hôpital Saint-Louis, two factors associated with such a potential operational cure were found: patients who received at least 2 years of ropeginterferon alfa-2b therapy with complete response, and the mutant allele burden of the JAK2 mutation.
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox